Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, on March 18, 2014 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company’s business highlights. Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares after opening at $19.05 moved to $19.05 on last trade day and at the end of the day closed at $17.28.Company price to cash ratio as 5.79. Aerie Pharmaceuticals Inc (NASDAQ:AERI) showed a negative weekly performance of -13.47%.
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that CEO Michael Clayman, M.D., will present an overview of the company at the 13th Annual Needham Healthcare Conference. Dr. Clayman’s presentation is scheduled for April 9, 2014, at 1:40 p.m. Eastern Time. The conference will take place April 8-9, 2014, at The Westin New York Grand Central. Flexion Therapeutics Inc (NASDAQ:FLXN) shares fell -1.94% in last trading session and ended the day on $16.65. FLXN return on equity ratio is recorded as 56.10% and its return on assets is -117.90%.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNX), a development stage pharmaceutical company, was spotlighted in the April 7, 2014 issue of BioCentury: The Bernstein Report on BioBusiness.An article titled “Confirming Endpoints” focused on the U.S. Food and Drug Administration’s (FDA) March 26 disease area meeting in which testimony from fibromyalgia (FM) patients was solicited. According to the article, patient testimony suggests that there is a need for better medicines because many patients said existing approved or off-label use drugs do not provide adequate relief.Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNX) shares moved down -6.38% in last trading session and was closed at $10.42, while trading in range of $10.03-$11.11. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNX) year to date performance is 1.07%.
NanoViricides Inc (NYSEMKT:NNVC) announced on March 31,2014 that Anil R. Diwan, Ph.D., President, Chairman, and co-Founder of the Company was recognized as the “2014 Researcher of the Year” by BusinessNewHaven, a business journal, and New Haven Magazine, publications that serve the state of Connecticut. NanoViricides Inc (NYSEMKT:NNVC) weekly performance is 14.33%. On last trading day company shares ended up $3.51. NanoViricides Inc (NYSEMKT:NNVC) distance from 50-day simple moving average is -8.13%. Analysts mean target price for the company is $7.21.
Leave a Reply